Review
Anoikis molecular pathways and its role in cancer progression

https://doi.org/10.1016/j.bbamcr.2013.06.026Get rights and content
Under an Elsevier user license
open archive

Highlights

  • Anoikis is a hallmark of cancer enabling tumor cells with metastatic skills.

  • Cancer cells exploit different strategies to overcome anoikis.

  • miRNA modulation and metabolic adaptation correlate with anoikis resistance.

  • Oxidative stress and hypoxia favor cell escaping from anoikis.

  • Anoikis insensitivity provides several advantages alongside the metastatic pathway.

Abstract

Anoikis is a programmed cell death induced upon cell detachment from extracellular matrix, behaving as a critical mechanism in preventing adherent-independent cell growth and attachment to an inappropriate matrix, thus avoiding colonizing of distant organs. As anchorage-independent growth and epithelial–mesenchymal transition, two features associated with anoikis resistance, are vital steps during cancer progression and metastatic colonization, the ability of cancer cells to resist anoikis has now attracted main attention from the scientific community. Cancer cells develop anoikis resistance due to several mechanisms, including change in integrins' repertoire allowing them to grow in different niches, activation of a plethora of inside-out pro-survival signals as over-activation of receptors due to sustained autocrine loops, oncogene activation, growth factor receptor overexpression, or mutation/upregulation of key enzymes involved in integrin or growth factor receptor signaling. In addition, tumor microenvironment has also been acknowledged to contribute to anoikis resistance of bystander cancer cells, by modulating matrix stiffness, enhancing oxidative stress, producing pro-survival soluble factors, triggering epithelial–mesenchymal transition and self-renewal ability, as well as leading to metabolic deregulations of cancer cells. All these events help cancer cells to inhibit the apoptosis machinery and sustain pro-survival signals after detachment, counteracting anoikis and constituting promising targets for anti-metastatic pharmacological therapy. This article is part of a Special Section entitled: Cell Death Pathways. Guest Editors: Frank Madeo and Slaven Stekovic.

Abbreviations

AMPK
AMP activated protein kinase
ECM
extracellular matrix
EGFR
epidermal growth factor receptor
EMT
epithelial–mesenchymal transition
ERK
extracellular signal-regulated kinase
FLIP
FLICE inhibitory protein
FAK
focal adhesion kinase
GSK-3
glycogen synthase kinase-3
HGF
hepatocyte growth factor
HIF
hypoxia-inducible factor
IL
interleukin
ILK
integrin-linked kinase
IKK
IκB kinase
MAPK
mitogen activated protein kinase
Mcl-1
myeloid cell leukemia sequence 1
MET
mesenchymal epithelial transition
MMP
metalloproteinase
NFκB
nuclear factor-κB
Nox
NADPH oxidase
OMM
outer mitochondrial membrane
PDGFR
platelet-derived growth factor receptor
PDK
pyruvate dehydrogenase kinase
PERK
protein kinase like endoplasmic reticulum kinase
PI3K
phosphoinositide-3-OH kinase
PIP3
phosphatidylinositol 3,4,5-triphosphate
PKB
protein kinase B
PK-M2
pyruvate kinase isoform-2
PPP
pentose phosphate pathway
PTEN
phosphatase and tensin homolog
ROS
reactive oxygen species
RTKs
receptor tyrosine kinases
SMA
α-smooth muscle actin
TNFR
tumor necrosis factor receptor
TrkB
tyrosine kinase receptor B
VEGFR
vascular endothelial growth factor receptor

Keywords

Anoikis
Cancer
MicroRNA
Metabolism
Reactive oxygen species

Cited by (0)

This article is part of a Special Section entitled: Cell Death Pathways. Guest Editors: Frank Madeo and Slaven Stekovic.